CMS Hemp CBD Program Faces Physician Certification Gap as MMJ Appeal Pends

Physician Certification Requirements Create Bottleneck

CMS requires physicians to hold active DEA registrations and complete agency-approved training modules before certifying Medicare beneficiaries for hemp CBD coverage, but fewer than 2,400 physicians nationwide have completed the certification process since the program launched in May 2026. The certification pathway, outlined in CMS Program Memorandum AB-26-047, mandates a 12-hour continuing medical education course focused on cannabinoid pharmacology and federal compliance protocols.

The physician shortage hits hardest in rural counties and states without operational medical marijuana programs. Montana, Wyoming, and South Dakota each report fewer than 15 certified physicians statewide. Urban centers fare better—Los Angeles County alone accounts for 340 certified physicians—though access remains uneven within metropolitan service areas.

CMS spokesperson Patricia Navarro said the agency's monitoring enrollment data and may adjust training requirements in the 2027 rulemaking cycle. She provided no timeline.

Medical Marijuana Certification Appeal Remains in Administrative Review

A separate administrative appeal filed by the American Medical Marijuana Physicians Association in March 2026 challenges CMS's refusal to recognize state-licensed medical marijuana certifications as equivalent to the federal hemp CBD pathway. The appeal, docketed as CMS-ALJ-2026-00834, argues that physicians already authorized under state medical cannabis programs possess sufficient expertise to certify hemp CBD patients without duplicative federal training.

Administrative Law Judge Raymond Cho in the Baltimore field office is reviewing the case. No hearing date has been set. AMMPA represents approximately 8,700 physicians across 38 medical marijuana states.

CMS has opposed the appeal in written briefs, citing statutory distinctions between Schedule I substances (marijuana) and hemp-derived products lawful under the 2018 Farm Bill. Federal training ensures uniform patient safety standards across state lines, the agency maintains.

Program Enrollment Lags Projections by 40 Percent

CMS projected 180,000 Medicare beneficiaries would enroll in hemp CBD coverage by September 2026, but actual enrollment through August 31 totaled 107,600 beneficiaries. The shortfall stems primarily from physician access barriers in 22 states where fewer than 50 certified physicians practice.

Enrollment concentrates in states with mature medical marijuana infrastructure. California leads with 23,400 enrolled beneficiaries, followed by Florida (18,200) and Colorado (11,900). States without medical marijuana programs account for less than 8 percent of total enrollment despite representing 22 percent of the Medicare population.

The program covers hemp-derived CBD products containing no more than 0.3 percent delta-9 THC for FDA-approved indications including epilepsy, chronic pain, and anxiety disorders. Beneficiaries pay a 20 percent coinsurance after meeting the Part B deductible.

Training Capacity Constraints Slow Physician Onboarding

The required 12-hour CME course is offered by only four CMS-approved providers, creating scheduling bottlenecks that delay physician certification by an average of 6.4 weeks from application to approval. Two of the four providers—MedEd Solutions and Clinical Cannabis Institute—have waitlists exceeding 800 physicians as of September 10.

The American Medical Association and American Academy of Family Physicians have requested that CMS expand the approved-provider list and allow asynchronous online completion of training modules. CMS hasn't responded publicly to those requests.

Physicians in states with existing medical marijuana CME infrastructure report frustration with duplicative federal requirements. Dr. Ellen Ramirez, a family medicine physician in Denver who holds both Colorado medical marijuana and CMS hemp CBD certifications, said the federal course covered material identical to her state-mandated training completed in 2024.

Reimbursement Rates Deter Physician Participation

CMS reimburses physicians $58.32 per patient certification visit under CPT code 99215, a rate that practice administrators say doesn't cover the time required for documentation and compliance reporting. The certification process requires physicians to submit detailed treatment plans, monitor patient outcomes quarterly, and maintain records for seven years under 42 CFR § 410.78.

Practice overhead for hemp CBD certification averages $74 per patient visit when accounting for staff time and electronic health record modifications, according to a survey of 240 participating practices conducted by the Medical Group Management Association in August 2026. That negative margin is driving some physicians to limit the number of hemp CBD patients they accept. Others decline participation altogether.

Physician advocacy groups have petitioned CMS to increase the reimbursement rate to $92, aligning it with complex chronic care management codes. The agency hasn't indicated whether it'll address reimbursement in the 2027 Physician Fee Schedule proposed rule, expected in November 2026.

What Comes Next for the Hemp CBD Program

CMS is required to submit a program evaluation report to Congress by December 31, 2026, under Section 1862(a)(1)(A) of the Social Security Act. The report will assess enrollment trends, physician participation rates, and patient outcomes data from the program's first nine months. Congressional appropriators have signaled that future funding may depend on the program meeting enrollment benchmarks.

A decision on the administrative appeal regarding medical marijuana physician equivalency is expected by early 2027. If AMMPA prevails, the ruling could immediately expand the pool of eligible certifying physicians by more than 8,000 practitioners. If CMS prevails, the current training pathway will remain the sole route to federal certification.

Industry observers expect CMS to propose regulatory changes in the spring 2027 rulemaking cycle, potentially including streamlined training for physicians with state cannabis credentials and expanded CME provider approval. The agency hasn't confirmed those plans.